Fundraising Fox

Iksuda Therapeutics

1 known investors

Find your way into Iksuda Therapeutics

Iksuda develops antibody-drug conjugates (ADCs) with enhanced tumor specificity for treating difficult-to-treat cancers. The company designs class-leading ADC therapeutics incorporating novel payloads and platform technologies optimized for anti-cancer efficacy and patient safety.

BiotechDeep TechMedical Devices

Investors · 1

Premier PartnersSeoul

In the news

Iksuda Therapeutics raises £34 million to expand conjugation platform technologies - European Pharmaceutical Manufacturerpharmaceuticalmanufacturer.media · Jun 2021Iksuda Therapeutics Raises $47M in Funding - FinSMEsfinsmes.com · Jun 2021IP : Portfolio Company Iksuda Therapeutics Raises $42 Million | MarketScreenermarketscreener.com · Jun 2021Iksuda Therapeutics Closes $47 Million Financing Round - BioSpacebiospace.com · Jun 2021Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Fierce Biotechfiercebiotech.com · Jun 2021Newcastle's Iksuda Therapeutics raises $47m funding to ramp up cancer drug developmentinkl.com · Jun 2021

Frequently asked questions

What does Iksuda Therapeutics do?
Iksuda develops antibody-drug conjugates (ADCs) with enhanced tumor specificity for treating difficult-to-treat cancers. The company designs class-leading ADC therapeutics incorporating novel payloads and platform technologies optimized for anti-cancer efficacy and patient safety.
Who are Iksuda Therapeutics's investors?
Iksuda Therapeutics's investors include Premier Partners.